title: Increased expression of thrombomodulin on the cultured human umbilical vein endothelial cells and mouse hemangioma cells by cyclic AMP.
abstract: We previously reported that the expression of thrombomodulin on the MEG-01, a cell line from human megakaryoblastic leukemia, was increased by agents that increase intracellular cAMP. In this paper we examine the effect of these agents on cultured human umbilical vein endothelial cells (HUVEC) and mouse hemangioma cells. Incubation of the cells with 3 mM dibutyryl cAMP (dbcAMP) increased functionally active thrombomodulin by about 2-fold on HUVEC and 4-fold on hemangioma cells. This effect was observed from 1 hour after the incubation and continued up to 24 hours. Dot hybridization of mRNA demonstrated a dose dependent increase in thrombomodulin mRNA in response to dbcAMP. Treatment of HUVEC with 20 microM forskolin or 100 microM isobutylmethylxanthine (IBMX) also increased cell-surface thrombomodulin on HUVEC. These agents prevented the interleukin I (IL-I) or tumor necrosis factor (TNF)-induced decrease in thrombomodulin on HUVEC. These data suggest that the expression of thrombomodulin on HUVEC and mouse hemangioma cells may be regulated by intracellular cAMP level.
authors.affiliation: Third Department of Internal Medicine, Kagoshima University School of Medicine, Japan.
authors.forename: I
authors.initials: I
authors.lastname: Maruyama
authors.forename: Y
authors.initials: Y
authors.lastname: Soejima
authors.forename: M
authors.initials: M
authors.lastname: Osame
authors.forename: T
authors.initials: T
authors.lastname: Ito
authors.forename: K
authors.initials: K
authors.lastname: Ogawa
authors.forename: S
authors.initials: S
authors.lastname: Yamamoto
authors.forename: W A
authors.initials: WA
authors.lastname: Dittman
authors.forename: H
authors.initials: H
authors.lastname: Saito
mesh_terms: D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D000818:Animals; D003994:Bucladesine / Q000494:pharmacology*; D002478:Cells, Cultured / Q000187:drug effects; D005576:Colforsin / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000378:metabolism; D006391:Hemangioma; D006801:Humans; D007375:Interleukin-1 / Q000037:antagonists & inhibitors; D051379:Mice; D012333:RNA, Messenger / Q000032:analysis*; D011956:Receptors, Cell Surface / Q000096:biosynthesis* / Q000235:genetics; D018179:Receptors, Thrombin; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014471:Umbilical Veins
chemical_list: D007375:Interleukin-1; D012333:RNA, Messenger; D011956:Receptors, Cell Surface; D018179:Receptors, Thrombin; D014409:Tumor Necrosis Factor-alpha; D005576:Colforsin; D003994:Bucladesine; D015056:1-Methyl-3-isobutylxanthine